Design And Evaluation Of Nanocarrier-Integrated Transdermal Patch For Glimepiride In Type 2 Diabetes

Abstract

The increasing prevalence of type 2 diabetes necessitates innovative drug delivery systems to improve therapeutic outcomes and patient compliance. This study focuses on the design and evaluation of a nanocarrier-integrated transdermal patch for the delivery of glimepiride, a widely used oral antidiabetic agent. Nanocarriers, owing to their nanoscale size and enhanced surface properties, were developed using a solvent evaporation technique and loaded with glimepiride to optimize drug encapsulation and controlled release. The prepared nanocarriers were carefully characterized for particle size, zeta potential, and entrapment efficiency prior to their incorporation into an optimized transdermal patch matrix. The resultant patches were evaluated for physicochemical properties, in vitro drug release, ex vivo skin permeation, and stability to ensure consistency and efficacy. In vivo studies in diabetic animal models demonstrated sustained drug release, improved glycemic control, and minimized skin irritation relative to conventional systems. Overall, the nanocarrier-integrated transdermal patch offers a promising strategy for non-invasive, controlled, and effective glimepiride administration in type 2 diabetes, potentially improving patient adherence and therapeutic efficacy.